Ben Folwell

Director, BD&L Lead at Norstella

Speaker

Ben is Director BD&L Lead in the Consulting team at Evaluate. With a specialization in quantitative analysis, Ben leads projects covering buy and sell side due diligence, deal benchmarking, pipeline tracking, competitor analysis and product forecasting across a broad range of indications and markets, with an increasing focus on rare diseases. Recent work has included building prioritization models that can be used to identify in-licensing opportunities, out licensing partners, attractive indications, or technologies. Ben has authored of a number of peer reviewed journal articles and industry standard guideline documents, including co-authorship of “Study on the impact of mergers and acquisitions on innovation in the pharmaceutical sector” and "Study in support of the Evaluation and Impact Assessment of the EU general pharmaceutical legislation" for the European Commission.